Rare Case of Acquired Haemophilia A Associated with COVID-19 Vaccine

Strategic Insights -

Researchers at the Gottingen University Medical Center in Gottingen, Germany, have described a rare case of acquired haemophilia A following mRNA-1273 booster vaccination against SARS-CoV-2 with concurrent diagnosis of pleomorphic dermal sarcoma. The case report highlights the challenges in rare events occurring in association with SARS-CoV-2 vaccination and the need for reporting any events related to COVID-19 vaccination.

Key Takeaways:

  • A 73-year-old patient developed acquired haemophilia A after receiving the mRNA-1273 booster vaccination against SARS-CoV-2.
  • The patient's condition was diagnosed promptly, and they received appropriate treatment, including immunosuppression using glucocorticoids, cyclophosphamide, and rituximab.
  • The patient's hemorrhage ceased after escalation of treatment, and they are recovering.
  • Pleomorphic dermal sarcoma of the forehead occurred after initiation of specific AHA immunosuppressive treatment.
  • This case illustrates challenges in rare events occurring in association with SARS-CoV-2 vaccination and the need for reporting any events in association with SARS-CoV-2 vaccination.
  • The researchers emphasize the importance of post-marketing surveillance to record rare safety issues related to new vaccines.

Statistics:

  • The patient was 73 years old when they developed acquired haemophilia A.
  • The patient received the mRNA-1273 booster vaccination against SARS-CoV-2.
  • The patient's condition was diagnosed promptly, and they received treatment using glucocorticoids, cyclophosphamide, and rituximab.
  • The patient's hemorrhage ceased after escalation of treatment.
  • The patient is recovering.

Sources:

  • Case Report: Acquired Haemophilia A Following mRNA-1273 Booster Vaccination Against SARS-CoV-2 With Concurrent Diagnosis of Pleomorphic Dermal Sarcoma. Frontiers in Immunology, 2022,13. (Frontiers in Immunology - http://journal.frontiersin.org/journal/immunology)
  • Gottingen University Medical Center, Gottingen, Germany
  • Frontiers in Immunology, Frontiers Media S.A.